Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1314

1.

Familial Clustering, Second Primary Cancers and Causes of Death in Penile, Vulvar and Vaginal Cancers.

Zhang L, Hemminki O, Chen T, Zheng G, Försti A, Sundquist K, Sundquist J, Hemminki K.

Sci Rep. 2019 Aug 14;9(1):11804. doi: 10.1038/s41598-019-48399-4.

2.

Analysis of 153,115 patients with hematological malignancies refines the spectrum of familial risk.

Sud A, Chattopadhyay S, Thomsen H, Sundquist K, Sundquist J, Houlston RS, Hemminki K.

Blood. 2019 Aug 8. pii: blood.2019001362. doi: 10.1182/blood.2019001362. [Epub ahead of print]

PMID:
31395603
3.

Familial Cancer: How to Successfully Recruit Families for Germline Mutations Studies? Multiple Myeloma as an Example.

Blocka J, Durie BGM, Huhn S, Mueller-Tidow C, Försti A, Hemminki K, Goldschmidt H.

Clin Lymphoma Myeloma Leuk. 2019 Jul 4. pii: S2152-2650(19)30249-6. doi: 10.1016/j.clml.2019.06.012. [Epub ahead of print]

PMID:
31377209
4.

Familial Risks and Mortality in Second Primary Cancers in Melanoma.

Chattopadhyay S, Hemminki A, Försti A, Sundquist K, Sundquist J, Hemminki K.

JNCI Cancer Spectr. 2019 Jan 9;2(4):pky068. doi: 10.1093/jncics/pky068. eCollection 2018 Oct.

5.

Second primary cancers in patients with invasive and in situ squamous cell skin carcinoma, Kaposi sarcoma and Merkel cell carcinoma: role for immune mechanisms?

Chattopadhyay S, Hemminki A, Försti A, Sundquist K, Sundquist J, Hemminki K.

J Invest Dermatol. 2019 Jul 6. pii: S0022-202X(19)31854-8. doi: 10.1016/j.jid.2019.04.031. [Epub ahead of print]

PMID:
31288011
6.

Autoimmune diseases and hematological malignancies: Exploring the underlying mechanisms from epidemiological evidence.

Hemminki K, Huang W, Sundquist J, Sundquist K, Ji J.

Semin Cancer Biol. 2019 Jun 7. pii: S1044-579X(18)30181-0. doi: 10.1016/j.semcancer.2019.06.005. [Epub ahead of print] Review.

PMID:
31181268
7.

Correction: Single nucleotide polymorphisms within MUC4 are associated with colorectal cancer survival.

Lu S, Catalano C, Huhn S, Pardini B, Bartu L, Vymetalkova V, Vodickova L, Levy M, Buchler T, Hemminki K, Vodicka P, Försti A.

PLoS One. 2019 Jun 6;14(6):e0218064. doi: 10.1371/journal.pone.0218064. eCollection 2019.

8.

Familial Urinary Bladder Cancer with Other Cancers.

Yu H, Hemminki O, Försti A, Sundquist K, Hemminki K.

Eur Urol Oncol. 2018 Dec;1(6):461-466. doi: 10.1016/j.euo.2018.06.002. Epub 2018 Jun 30.

PMID:
31158089
9.

Single nucleotide polymorphisms within MUC4 are associated with colorectal cancer survival.

Lu S, Catalano C, Huhn S, Pardini B, Partu L, Vymetalkova V, Vodickova L, Levy M, Buchler T, Hemminki K, Vodicka P, Försti A.

PLoS One. 2019 May 15;14(5):e0216666. doi: 10.1371/journal.pone.0216666. eCollection 2019. Erratum in: PLoS One. 2019 Jun 6;14(6):e0218064.

10.

Second primary cancers in non-Hodgkin lymphoma: Family history and survival.

Chattopadhyay S, Zheng G, Sud A, Sundquist K, Sundquist J, Försti A, Houlston R, Hemminki A, Hemminki K.

Int J Cancer. 2019 May 4. doi: 10.1002/ijc.32391. [Epub ahead of print]

PMID:
31054153
11.

Second cancers and causes of death in patients with testicular cancer in Sweden.

Zhang L, Hemminki O, Chen T, Yu H, Zheng G, Chattopadhyay S, Försti A, Sundquist K, Sundquist J, Hemminki K.

PLoS One. 2019 Mar 28;14(3):e0214410. doi: 10.1371/journal.pone.0214410. eCollection 2019.

12.

Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients.

Zheng G, Chattopadhyay S, Sud A, Sundquist K, Sundquist J, Försti A, Houlston RS, Hemminki A, Hemminki K.

Blood Cancer J. 2019 Mar 26;9(4):40. doi: 10.1038/s41408-019-0201-0. No abstract available.

13.

Update on genetic predisposition to colorectal cancer and polyposis.

Valle L, de Voer RM, Goldberg Y, Sjursen W, Försti A, Ruiz-Ponte C, Caldés T, Garré P, Olsen MF, Nordling M, Castellvi-Bel S, Hemminki K.

Mol Aspects Med. 2019 Mar 18. pii: S0098-2997(19)30004-4. doi: 10.1016/j.mam.2019.03.001. [Epub ahead of print] Review.

14.

Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma.

Chattopadhyay S, Thomsen H, Yadav P, da Silva Filho MI, Weinhold N, Nöthen MM, Hoffman P, Bertsch U, Huhn S, Morgan GJ, Goldschmidt H, Houlston R, Hemminki K, Försti A.

Commun Biol. 2019 Mar 4;2:89. doi: 10.1038/s42003-019-0329-2. eCollection 2019.

15.

Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma.

Thomsen H, Chattopadhyay S, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Hemminki K, Försti A.

Leukemia. 2019 Jul;33(7):1817-1821. doi: 10.1038/s41375-019-0396-x. Epub 2019 Feb 8. No abstract available.

PMID:
30737484
16.

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.

Zheng G, Chattopadhyay S, Sud A, Sundquist K, Sundquist J, Försti A, Houlston R, Hemminki A, Hemminki K.

Br J Haematol. 2019 Apr;185(2):232-239. doi: 10.1111/bjh.15777. Epub 2019 Jan 31.

PMID:
30706458
17.

Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia.

Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jöckel KH, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS.

Nat Commun. 2019 Jan 21;10(1):419. doi: 10.1038/s41467-018-08106-9.

18.

Familial Associations of Colon and Rectal Cancers With Other Cancers.

Yu H, Hemminki A, Sundquist K, Hemminki K.

Dis Colon Rectum. 2019 Feb;62(2):189-195. doi: 10.1097/DCR.0000000000001262.

PMID:
30640834
19.

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS.

Nat Commun. 2019 Jan 10;10(1):213. doi: 10.1038/s41467-018-08107-8.

20.

Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility.

Sud A, Thomsen H, Law PJ, Försti A, da Silva Filho MI, Holroyd A, Broderick P, Orlando G, Lenive O, Wright L, Cooke R, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Eeles R, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Hoffmann P, Nöthen MM, Jöckel KH, von Strandmann EP, Lightfoot T, Kane E, Roman E, Lake A, Montgomery D, Jarrett RF, Swerdlow AJ, Engert A, Orr N, Hemminki K, Houlston RS.

Nat Commun. 2019 Jan 8;10(1):157. doi: 10.1038/s41467-018-08105-w.

21.

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Went M, Sud A, Speedy H, Sunter NJ, Försti A, Law PJ, Johnson DC, Mirabella F, Holroyd A, Li N, Orlando G, Weinhold N, van Duin M, Chen B, Mitchell JS, Mansouri L, Juliusson G, Smedby KE, Jayne S, Majid A, Dearden C, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Kuiper R, Stephens OW, Bertsch U, Broderick P, Einsele H, Gregory WM, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Hansson M, Goldschmidt H, Dyer MJS, Kaiser M, Sonneveld P, Morgan GJ, Hemminki K, Nilsson B, Catovsky D, Allan JM, Houlston RS.

Blood Cancer J. 2018 Dec 21;9(1):1. doi: 10.1038/s41408-018-0162-8.

22.

Second primary cancer after female breast cancer: Familial risks and cause of death.

Zheng G, Hemminki A, Försti A, Sundquist J, Sundquist K, Hemminki K.

Cancer Med. 2019 Jan;8(1):400-407. doi: 10.1002/cam4.1899. Epub 2018 Nov 26.

23.

Levels of DNA damage (Micronuclei) in patients suffering from chronic kidney disease. Role of GST polymorphisms.

Pastor S, Rodríguez-Ribera L, Corredor Z, da Silva Filho MI, Hemminki K, Coll E, Försti A, Marcos R.

Mutat Res Genet Toxicol Environ Mutagen. 2018 Dec;836(Pt A):41-46. doi: 10.1016/j.mrgentox.2018.05.008. Epub 2018 May 8.

PMID:
30389161
24.

Genetic variation of acquired structural chromosomal aberrations.

Vodicka P, Musak L, Vodickova L, Vodenkova S, Catalano C, Kroupa M, Naccarati A, Polivkova Z, Vymetalkova V, Försti A, Hemminki K.

Mutat Res Genet Toxicol Environ Mutagen. 2018 Dec;836(Pt A):13-21. doi: 10.1016/j.mrgentox.2018.05.014. Epub 2018 May 19. Review.

PMID:
30389156
25.

Genetic variation associated with chromosomal aberration frequency: A genome-wide association study.

Niazi Y, Thomsen H, Smolkova B, Vodickova L, Vodenkova S, Kroupa M, Vymetalkova V, Kazimirova A, Barancokova M, Volkovova K, Staruchova M, Hoffmann P, Nöthen MM, Dušinská M, Musak L, Vodicka P, Hemminki K, Försti A.

Environ Mol Mutagen. 2019 Jan;60(1):17-28. doi: 10.1002/em.22236. Epub 2018 Oct 3.

PMID:
30368896
26.

Correction: Familial risks of ovarian cancer by age at diagnosis, proband type and histology.

Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K.

PLoS One. 2018 Oct 26;13(10):e0206721. doi: 10.1371/journal.pone.0206721. eCollection 2018.

27.

Familial risks of second primary cancers and mortality in ovarian cancer patients.

Zheng G, Chattopadhyay S, Försti A, Sundquist K, Hemminki K.

Clin Epidemiol. 2018 Oct 11;10:1457-1466. doi: 10.2147/CLEP.S174173. eCollection 2018.

28.

Clinical landscape of cancer metastases.

Riihimäki M, Thomsen H, Sundquist K, Sundquist J, Hemminki K.

Cancer Med. 2018 Nov;7(11):5534-5542. doi: 10.1002/cam4.1697. Epub 2018 Oct 16.

29.

Familial risks of ovarian cancer by age at diagnosis, proband type and histology.

Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K.

PLoS One. 2018 Oct 3;13(10):e0205000. doi: 10.1371/journal.pone.0205000. eCollection 2018. Erratum in: PLoS One. 2018 Oct 26;13(10):e0206721.

30.

Prostate cancer survivors: Risk and mortality in second primary cancers.

Chattopadhyay S, Zheng G, Hemminki O, Försti A, Sundquist K, Hemminki K.

Cancer Med. 2018 Nov;7(11):5752-5759. doi: 10.1002/cam4.1764. Epub 2018 Oct 1.

31.

Second primary cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction.

Chattopadhyay S, Sud A, Zheng G, Yu H, Sundquist K, Sundquist J, Försti A, Houlston R, Hemminki A, Hemminki K.

Int J Cancer. 2018 Nov 15;143(10):2449-2457. doi: 10.1002/ijc.31801. Epub 2018 Sep 21.

PMID:
30238973
32.

Importance of tumor location and histology in familial risk of upper gastrointestinal cancers: a nationwide cohort study.

Kharazmi E, Babaei M, Fallah M, Chen T, Sundquist K, Hemminki K.

Clin Epidemiol. 2018 Sep 4;10:1169-1179. doi: 10.2147/CLEP.S168152. eCollection 2018.

33.

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS; PRACTICAL consortium.

Nat Commun. 2018 Sep 13;9(1):3707. doi: 10.1038/s41467-018-04989-w. Erratum in: Nat Commun. 2019 Jan 10;10(1):213.

34.

Familial risk of pleural mesothelioma increased drastically in certain occupations: A nationwide prospective cohort study.

Kharazmi E, Chen T, Fallah M, Sundquist K, Sundquist J, Albin M, Weiderpass E, Hemminki K.

Eur J Cancer. 2018 Nov;103:1-6. doi: 10.1016/j.ejca.2018.07.139. Epub 2018 Sep 6.

PMID:
30196105
35.

Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.

Sud A, Thomsen H, Orlando G, Försti A, Law PJ, Broderick P, Cooke R, Hariri F, Pastinen T, Easton DF, Pharoah PDP, Dunning AM, Peto J, Canzian F, Eeles R, Kote-Jarai Z, Muir K, Pashayan N, Campa D; PRACTICAL Consortium, Hoffmann P, Nöthen MM, Jöckel KH, von Strandmann EP, Swerdlow AJ, Engert A, Orr N, Hemminki K, Houlston RS.

Blood. 2018 Nov 8;132(19):2040-2052. doi: 10.1182/blood-2018-06-855296. Epub 2018 Sep 7.

36.

Impact of family history of cancer on risk and mortality of second cancers in patients with prostate cancer.

Chattopadhyay S, Hemminki O, Försti A, Sundquist K, Sundquist J, Hemminki K.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):143-149. doi: 10.1038/s41391-018-0089-y. Epub 2018 Sep 5.

PMID:
30185889
37.

Outbreak of multiple strains of non-O157 Shiga toxin-producing and enteropathogenic Escherichia coli associated with rocket salad, Finland, autumn 2016.

Kinnula S, Hemminki K, Kotilainen H, Ruotsalainen E, Tarkka E, Salmenlinna S, Hallanvuo S, Leinonen E, Jukka O, Rimhanen-Finne R.

Euro Surveill. 2018 Aug;23(35). doi: 10.2807/1560-7917.ES.2018.23.35.1700666.

38.

Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults.

McGee EE, Castro FA, Engels EA, Freedman ND, Pfeiffer RM, Nogueira L, Stolzenberg-Solomon R, McGlynn KA, Hemminki K, Koshiol J.

Int J Cancer. 2019 Feb 15;144(4):707-717. doi: 10.1002/ijc.31835. Epub 2018 Nov 8.

PMID:
30155920
39.

Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study.

Chattopadhyay S, Thomsen H, da Silva Filho MI, Weinhold N, Hoffmann P, Nöthen MM, Marina A, Jöckel KH, Schmidt B, Pechlivanis S, Langer C, Goldschmidt H, Hemminki K, Försti A.

Mol Med. 2018 Jun 11;24(1):30. doi: 10.1186/s10020-018-0031-8.

40.

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.

Ann Oncol. 2018 Aug 1;29(8):1658-1686. doi: 10.1093/annonc/mdy217.

PMID:
30113631
41.

Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.

Mahmoudpour SH, Bandapalli OR, da Silva Filho MI, Campo C, Hemminki K, Goldschmidt H, Merz M, Försti A.

BMC Cancer. 2018 Aug 15;18(1):820. doi: 10.1186/s12885-018-4728-4.

42.

HLA and KIR Associations of Cervical Neoplasia.

Bao X, Hanson AL, Madeleine MM, Wang SS, Schwartz SM, Newell F, Pettersson-Kymmer U, Hemminki K, Tiews S, Steinberg W, Rader JS, Castro F, Safaeian M, Franco EL, Coutlée F, Ohlsson C, Cortes A, Marshall M, Mukhopadhyay P, Cremin K, Johnson LG, Garland SM, Tabrizi SN, Wentzensen N, Sitas F, Trimble C, Little J, Cruickshank M, Frazer IH, Hildesheim A, Brown MA, Duncan EL, Sun YP, Leo PJ.

J Infect Dis. 2018 Nov 5;218(12):2006-2015. doi: 10.1093/infdis/jiy483.

PMID:
30099516
43.

Multiple myeloma: family history and mortality in second primary cancers.

Chattopadhyay S, Yu H, Sud A, Sundquist J, Försti A, Hemminki A, Hemminki K.

Blood Cancer J. 2018 Aug 7;8(8):75. doi: 10.1038/s41408-018-0108-1. No abstract available.

44.

Correction: Inherited variants in genes somatically mutated in thyroid cancer.

Campo C, Köhler A, Figlioli G, Elisei R, Romei C, Cipollini M, Bambi F, Hemminki K, Gemignani F, Landi S, Försti A.

PLoS One. 2018 Aug 7;13(8):e0202208. doi: 10.1371/journal.pone.0202208. eCollection 2018.

45.

Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden.

Chattopadhyay S, Zheng G, Sud A, Yu H, Sundquist K, Sundquist J, Försti A, Hemminki A, Houlston R, Hemminki K.

Lancet Haematol. 2018 Aug;5(8):e368-e377. doi: 10.1016/S2352-3026(18)30108-X.

PMID:
30075833
46.

Familial Cancer Variant Prioritization Pipeline version 2 (FCVPPv2) applied to a papillary thyroid cancer family.

Kumar A, Bandapalli OR, Paramasivam N, Giangiobbe S, Diquigiovanni C, Bonora E, Eils R, Schlesner M, Hemminki K, Försti A.

Sci Rep. 2018 Aug 2;8(1):11635. doi: 10.1038/s41598-018-29952-z.

47.

Familial Ovarian Cancer Clusters with Other Cancers.

Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K.

Sci Rep. 2018 Aug 1;8(1):11561. doi: 10.1038/s41598-018-29888-4.

48.

Familial Associations in Testicular Cancer with Other Cancers.

Zhang L, Yu H, Hemminki O, Försti A, Sundquist K, Hemminki K.

Sci Rep. 2018 Jul 18;8(1):10880. doi: 10.1038/s41598-018-28819-7.

49.

Borderline Ovarian Tumors Share Familial Risks with Themselves and Invasive Cancers.

Zheng G, Yu H, Kanerva A, Försti A, Sundquist K, Hemminki K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1358-1363. doi: 10.1158/1055-9965.EPI-18-0503. Epub 2018 Jul 17.

PMID:
30018148
50.

Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.

Sud A, Chattopadhyay S, Thomsen H, Sundquist K, Sundquist J, Houlston RS, Hemminki K.

Blood. 2018 Aug 30;132(9):973-976. doi: 10.1182/blood-2018-06-858597. Epub 2018 Jul 10. No abstract available.

Supplemental Content

Loading ...
Support Center